|
P R E - S Y M P O S I U M |
|
|
|
|
|
|
|
| Day 1 |
February 22, 2011 (Tuesday) |
|
| 7.30 |
Registration |
|
| 8.30 |
Opening Ceremonies
Introduction of the Objectives and the Expected Outcome of the Regional Training Course
|
|
| 9.00 |
SESSION 1: INTRODUCTION |
|
|
1.1 Radiation Therapy Principles |
Dr. G. Stevens |
|
a) Clinical Indications and Outcomes |
|
|
b) Applied Radiobiology |
|
|
1.2 Current Situation and Perspectives in Region/Country of Interest |
Dr. L. Lacanilao |
|
a) Clinical (Common Cancers and Stage at Presentation) |
|
|
b) Technical and Human Resource Availability/Competency |
|
|
c) Sustainability Issues |
|
|
1.3 Introduction of the Project and the Roles of the Participants |
Dr. M. Calaguas |
|
1.4 Evolution of Radiation Therapy from 2D to 3DCRT (to IMRT) |
Dr. J. Van Dyk |
|
a) Steps in the Radiation Therapy Process |
|
|
b) Cobalt Therapy versus Linear Accelerator |
|
|
c) Description of Differences from 2D to 3DCRT to IMRT |
|
|
d) Appropriate Patient Selection (2D to 3DCRT and 3DCRT to IMRT |
|
|
1.5 Milestones |
Dr. G. Stevens |
| 10.00 |
Discussion for Session 1 (Interaction with Participants) |
|
| 10.15 |
Coffee Break |
|
| 10.30 |
SESSION 2: DEFINITION OF TARGET VOLUME AND ORGANS AT RISK |
Dr. J. Van Dyk |
|
2.1 ICRU 50, 62, 71, 83 |
|
|
2.2 Defining Margins (CTV to ITV to PTV; OAR to PTV) |
|
|
a) Margins due to Microscopic Disease Extension |
|
|
b) Motion Management |
|
| 11.15 |
Discussion for Session 2 |
|
| 11.30 |
SESSION 3: PATIENT SET-UP AND IMMOBILIZATION |
Dr. G. Stevens |
|
a) Principles of Immobilization for Accurate Set-up |
|
|
b) Immobilization Compromises in the Bore of a Diagnostic CT |
|
| 12.00 |
Lunch |
|
| 1.00 |
SESSION 4: IMAGING FOR TARGET VOLUME AND OAR DETERMINATION |
Dr. J. Van Dyk |
|
4.1 Conventional Simulation |
|
|
4.2 CT Simulation |
|
|
a) Positioning (changes from 2D to 3DCRT) |
|
|
b) CT Imaging Parameters (slice thickness, contrast, etc) |
|
|
c) Data Transfer |
|
|
d) Conversion of CT numbers to Relative Electron Densities |
|
|
4.3 Use of Other Modalities (MR, SPECT, PET, etc) |
|
|
a) Image Fusion/Registration |
|
| 2.00 |
Discussion for Sessions 3 and 4 |
|
| 2.15 |
SESSION 5: PLAN EVALUATION |
Dr. G. Stevens |
|
a) Dmin, Dmean, Dmax |
|
|
b) Dose-volume histogram (frequency and cumulative) |
|
|
c) Dose-volume constraints |
|
|
d) Documentation, recording and reporting |
|
| 3.00 |
Discussion for Session 5 |
|
|
|
|
| Day 2 |
February 23, 2011 (Wednesday) |
|
| 8.00 |
SESSION 1: TREATMENT PLANNING |
Dr. J. Van Dyk |
|
a) From 2D to 3DCRT (to IMRT) |
|
|
b) Forward and Inverse Planning |
|
|
c) Beam Arrangement (isocentric vs SSD, non-coplanar, field matching) |
|
|
d) Virtual Simulation, DRRs, DCRs |
|
|
e) Dose Computation (tissue inhomogeneity corrections) |
|
|
f) Treatment Optimization |
|
|
g) Independent Verification |
|
|
h) Transfer to Delivery System and/or R&V system |
|
| 9.00 |
Discussion for Session 1 |
|
| 9.15 |
SESSION 2: TREATMENT PLANNING CLINICAL EXAMPLES (CASES, COMPARISONS, ETC) |
Dr. G. Stevens |
|
a) Breast |
|
|
b) Head and neck |
|
|
c) Genitourinary |
|
|
d) Gastrointestinal |
|
|
e) Brain/CNS |
|
|
f) Lung (including motion considerations) |
|
| 10.15 |
Discussion for Session 2 |
|
| 10.30 |
Coffee Break |
|
| 10.45 |
SESSION 3: QA CONSIDERATIONS |
Dr. J. Van Dyk / |
|
a) Patient specific QA |
Dr. G. Stevens |
|
b) Staffing/Training |
|
|
c) Appropriate patient selection |
|
|
d) Comprehensive QA |
|
|
e) Changes to documentation for intention, imaging, prescribing, recording and reporting |
|
| 11.45 |
Discussion for Session 3 |
|
| 12.00 |
Lunch Break |
|
|
STREAM FOR IAEA-REGISTERED PARTICIPANTS |
|
| 1.00 |
HANDS-ON/PRACTICALS |
|
|
1. Immobilization and Set-up (RO, MP; 15 min) |
|
|
2. Planning Image Acquisition using CT (RO, MP; 15 min) |
|
|
3. Treatment Planning (Available cases on GU, Brain/CNS, Head and Neck) |
|
|
a) Contouring (RO 60 min; MP 15 min for evaluation) |
|
|
b) Planning (MP 60 min; RO 15 min for evaluation) |
|
|
c) Plan evaluation (RO, MP; 30 min) |
|
|
4. Conventional simulation |
|
|
5. Data transfer (MP) |
|
|
6. Plan validation (MP 30 min with data transfer and documentation) |
|
|
7. Phantom study (specific machine and patient QA) |
|
|
8. Documentation (RO, MP) |
|
|
9. Positioning verification (MP, RO; 30 min with dosimetry) |
|
|
10. In vitro/in vivo dosimetry (MP) |
|
|
11. Wrap-up/discussion (15 min) |
|
|
|
|
| Note: |
The IAEA/RCA participants will be divided into two (2) groups: |
|
|
Group 1 |
|
|
with participants from the MSs with full CT-Sim capability will stay in center 1 (SLMC-BGC) |
|
|
Facilitators: Dr. C. Mendoza and Mr. JC Rojales |
|
|
Group 2 |
|
|
with participants from MSs with 2D (conventional simulation) will move to center 2 (SLMC-QC) |
|
|
Facilitators: Dr. K. Sy and Ms. Lilian Rodriguez, MSc |
|
|
|
|
|
STREAM FOR NON-IAEA-REGISTERED PARTICIPANTS |
|
| 1.00 |
HEAD AND NECK E-CONTOURING WORKSHOP |
Dr. K. Hu |
| Note: |
It is recommended that the attendees bring laptop computers which will be used to access Internet-based workshop content. |
|
|
S Y M P O S I U M P R O P E R |
|
|
|
|
| Day 3 |
February 24, 2011 (Thursday) |
|
| 7.30 |
Registration |
|
| 8.00 |
Opening Ceremonies |
|
| 8.30 |
LUNG CANCER |
Dr. R. Komaki |
|
1. Clinical Updates |
|
|
a) Staging |
|
|
b) Treatment Guidelines |
|
|
c) Patient Selection for Treatment |
|
|
d) Evidence-based Multimodality Treatment Protocols |
|
|
e) Current Clinical Trials and Outcomes |
|
|
f) Guidelines on the Rational Use of Technology for Staging, Treatment and Follow-up |
|
|
2. Physics |
Dr. J. Palta |
|
a) Patient Set-up and Immobilization |
|
|
b) Imaging for Target Volume and Organs At Risk Determination (4D, Prospective/Retrospective Gating) |
|
|
c) Definition of Target Volume and Organs at Risk |
|
|
d) Definition of Margins (CTV to ITV to PTV; OAR to PRV) |
|
|
e) Contouring and Prescribing for Specific Clinical Sites for 3DCRT |
|
|
f) Dose Prescription Methods for IMRT |
|
|
g) Treatment Planning |
|
|
h) Plan Evaluation |
|
|
i) Patient Specific QA |
|
| 10.00 |
Coffee Break and Opening of Exhibits |
|
| 10.30 |
LUNG CANCER CASE DISCUSSION |
Dr. R. Komaki |
|
a) Sample Clinical Cases |
|
|
b) Open Discussion |
|
| 12.00 |
Lunch Presentation (Fresenius Kabi) |
|
| 1.30 |
HEAD AND NECK CANCER |
Dr. K. Hu |
|
1. Clinical Updates |
|
|
a) Staging |
|
|
b) Treatment Guidelines |
|
|
c) Patient Selection for Treatment |
|
|
d) Evidence-based Multimodality Treatment Protocols |
|
|
e) Current Clinical Trials and Outcomes |
|
|
f) Guidelines on the Rational Use of Technology for Staging, Treatment and Follow-up |
|
|
2. Physics |
Dr. J. Palta |
|
a) Patient Set-up and Immobilization |
|
|
b) Imaging for Target Volume and Organs At Risk Determination (4D, Prospective/Retrospective Gating) |
|
|
c) Definition of Target Volume and Organs At Risk |
|
|
d) Definition of Margins (CTV to ITV to PTV; OAR to PRV) |
|
|
e) Contouring and Prescribing for Specific Clinical Sites for 3DCRT |
|
|
f) Dose Prescription Methods for IMRT |
|
|
g) Treatment Planning |
|
|
h) Plan Evaluation |
|
|
i) Patient Specific QA |
|
| 3.30 |
Coffee Break |
|
| 3.45 |
HEAD AND NECK CANCER CASE DISCUSSION |
Dr. K. Hu |
|
a) Sample Clinical Cases |
|
|
b) Open Discussion |
|
|
|
|
| 5.00 |
VARIAN Presentation |
|
|
Topic: Properties of Flattening Filter Free X-ray Beams by Mr. Joseph Ting, PhD |
|
| 5.30 |
IAEA Welcome Cocktails |
|
| 5.30 |
SEAROG Execom Meeting (Conference Room) |
|
| 7.00 |
Welcome Dinner (Varian) |
|
|
|
|
| Day 4 |
February 25, 2011 (Friday) |
|
|
7.30
|
Breakfast Symposium (FMEI) |
|
| 8.30 |
GASTROINTESTINAL CANCER |
Dr. D. Chang |
|
1. Clinical Updates |
|
|
a) Staging |
|
|
b) Treatment Guidelines |
|
|
c) Patient Selection for Treatment |
|
|
d) Evidence-based Multimodality Treatment Protocols |
|
|
e) Current Clinical Trials and Outcomes |
|
|
f) Guidelines on the Rational Use of Technology for Staging, Treatment and Follow-up |
|
|
2. Physics |
Dr. J. Palta |
|
a) Patient Set-up and Immobilization |
|
|
b) Imaging for Target Volume and Organs At Risk Determination (4D, Prospective/Retrospective Gating) |
|
|
c) Definition of Target Volume and Organs At Risk |
|
|
d) Definition of Margins (CTV to ITV to PTV; OAR to PRV) |
|
|
e) Contouring and Prescribing for Specific Clinical Sites for 3DCRT |
|
|
f) Dose Prescription Methods for IMRT |
|
|
g) Treatment Planning |
|
|
h) Plan Evaluation |
|
|
i) Patient Specific QA |
|
| 10.00 |
Working Coffee Break |
|
| 10.30 |
GASTROINTESTINAL CANCER CASE DISCUSSION |
Dr. D. Chang |
|
a) Sample Clinical Cases |
|
|
b) Open Discussion |
|
| 12.00 |
Group Picture Taking / Lunch Break (Siemens) |
|
| 1.30 |
BREAST CANCER |
Dr. J. Bellon |
|
1. Clinical Updates |
|
|
a) Staging |
|
|
b) Treatment Guidelines |
|
|
c) Patient Selection for Treatment |
|
|
d) Evidence-based Multimodality Treatment Protocols |
|
|
e) Current Clinical Trials and Outcomes |
|
|
f) Guidelines on the Rational Use of Technology for Staging, Treatment and Follow-up |
|
|
2. Physics |
Dr. J. Palta |
|
a) Patient Set-up and Immobilization |
|
|
b) Imaging for Target Volume and Organs At Risk Determination (4D, Prospective/Retrospective Gating) |
|
|
c) Definition of Target Volume and Organs At Risk |
|
|
d) Definition of Margins (CTV to ITV to PTV; OAR to PRV) |
|
|
e) Contouring and Prescribing for Specific Clinical Sites for 3DCRT |
|
|
f) Dose Prescription Methods for IMRT |
|
|
g) Treatment Planning |
|
|
h) Plan Evaluation |
|
|
i) Patient Specific QA |
|
| 3.30 |
Coffee Break |
|
| 3.45 |
BREAST CANCER CASE DISCUSSION |
Dr. J. Bellon |
|
a) Sample Clinical Cases |
|
|
b) Open Discussion |
|
|
|
|
| 5.00 |
INNOGEN Presentation |
|
| 5.30 |
Transfer to Manila Polo Club |
|
| 7.00 |
Fellowship Night (Innogen) at Manila Polo Club |
|
|
|
|
| Day 5 |
February 26, 2011 (Saturday) |
|
| 8.30 |
GENITOURINARY CANCER |
Dr. P. Warde |
|
1. Clinical Updates |
|
|
a) Staging |
|
|
b) Treatment Guidelines |
|
|
c) Patient Selection for Treatment |
|
|
d) Evidence-based Multimodality Treatment Protocols |
|
|
e) Current Clinical Trials and Outcomes |
|
|
f) Guidelines on the Rational Use of Technology for Staging, Treatment and Follow-up |
|
|
2. Physics |
Dr. J. Palta |
|
a) Patient Set-up and Immobilization |
|
|
b) Imaging for Target Volume and Organs At Risk Determination (4D, Prospective/Retrospective Gating) |
|
|
c) Definition of Target Volume and Organs At Risk |
|
|
d) Definition of Margins (CTV to ITV to PTV; OAR to PRV) |
|
|
e) Contouring and Prescribing for Specific Clinical Sites for 3DCRT |
|
|
f) Dose Prescription Methods for IMRT |
|
|
g) Treatment Planning |
|
|
h) Plan Evaluation |
|
|
i) Patient Specific QA |
|
| 10.00 |
Coffee Break |
|
| 10.30 |
GENITOURINARY CANCER CASE DISCUSSION |
Dr. P. Warde |
|
a) Sample Clinical Cases |
|
|
b) Open Discussion |
|
| 12.00 |
Lunch Break (Merck Serono and Merck Sharp and Dohme) |
|
| 1.00 |
Special Lecture: Heavy Ion Therapy |
Dr. T. Nakano |
| 2.00 |
Special Lecture: The Shift from 2D to Proton Beam Therapy |
Dr. J. Cox |
| 3.00 |
Participants' Evaluation and Training Assessment |
|
| 3.30 |
Closing Ceremonies |
|
|
|
|
|
FACULTY |
|
|
ASTRO
|
|
|
Jennifer Bellon, MD |
|
|
Daniel Chang, MD |
|
|
James Cox, MD |
|
|
Kenneth Hu, MD |
|
|
Ritsuko Komaki, MD |
|
|
Jatinder Palta, PhD |
|
|
Padraig Warde, MD |
|
|
IAEA
|
|
|
Graham Stevens, MD
|
|
|
Jacob Van Dyk, PhD
|
|
|
Takashi Nakano, MD |
|
Activities 
